Tg Therapeutics (TGTX) Stock Price, Quote & News

Company Profile

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. The company provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The com...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 554 4484

Fax: 212 554 4531

Website: www.tgtherapeutics.com

Address:

3020 Carrington Mill Blvd., Suite 475, Morrisville, United States

Cedenmo Sep. 10 at 3:59 PM

$TGTX I’m glad Agrawal asked about peak sales. Felt like he was trying to either jump start the stock price and/or trigger buyer interest?

1 · Reply

OlDocAngus Sep. 10 at 3:21 PM

$TGTX Neither do I.

0 · Reply

OlDocAngus Sep. 10 at 3:18 PM

$TGTX You can say whatever you want about President Trump but you can’t say he doesn’t have a sense of humor. lol https://www.thegatewaypundit.com/2026/09/pure-gold-trump-talarico-he-ran-campaign-beat/

1 · Reply

StockDreamin Sep. 10 at 2:49 PM

$TGTX cmon cmon

0 · Reply

ngyojiw Sep. 10 at 1:59 PM

$TGTX this drops faster than the overbought s&P lol

0 · Reply

Chartist0_0 Sep. 10 at 1:54 PM

$TGTX $XBI The bloom is off the XBI rose. Time to take cover.

1 · Reply

FUDrucker100 Sep. 10 at 1:47 PM

$TGTX wen $60? Wen moon?

4 · Reply

RookieRider Sep. 10 at 1:14 PM

$TGTX on vacation this week in Maine guys and gals. I see we are fading a bit. Need TG to rise so can get another monster Lobster 🦞

1 · Reply

NetworkNewsWire Sep. 10 at 1:12 PM

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market $QNTM $NVS $MRK $TGTX $BMY https://ibn.fm/A7zHr

1 · Reply

stu Sep. 10 at 12:40 PM

$TGTX https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-participate-hc-wainwright-28th-annual-global

0 · Reply

TG Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Sep 9, 2026, 11:30 AM EDT - 1 day ago

TG Therapeutics Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2026, 7:30 AM EDT - 7 days ago

TG Therapeutics to Participate in the Cantor Global Healthcare Conference

Aug 3, 2026, 8:30 AM EDT - 5 weeks ago

TG Therapeutics Earnings Call Transcript: Q2 2026

Aug 3, 2026, 8:30 AM EDT - 5 weeks ago

TG Therapeutics Earnings release: Q2 2026

Aug 3, 2026, 8:30 AM EDT - 5 weeks ago

TG Therapeutics Quarterly report: Q2 2026

Aug 3, 2026, 7:00 AM EDT - 5 weeks ago

TG Therapeutics Reports Second Quarter 2026 Financial Results and Raises BRIUMVI® Revenue Guidance

Jul 29, 2026, 7:30 AM EDT - 6 weeks ago

TG Therapeutics to Host Conference Call on Second Quarter 2026 Financial Results and Business Update

Jul 6, 2026, 7:30 AM EDT - 2 months ago

TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia

Jun 11, 2026, 9:30 AM EDT - 3 months ago

TG Therapeutics Transcript: AGM 2026

Jun 9, 2026, 2:00 PM EDT - 3 months ago

TG Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 9, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial

Jun 3, 2026, 11:40 AM EDT - 3 months ago

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 3, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)

Jun 2, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference

Jun 1, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology

May 28, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 27, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial

May 26, 2026, 7:30 AM EDT - 3 months ago

TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting

May 6, 2026, 8:30 AM EDT - 4 months ago

TG Therapeutics Earnings Call Transcript: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

TG Therapeutics Earnings release: Q1 2026

May 6, 2026, 8:30 AM EDT - 4 months ago

TG Therapeutics Quarterly report: Q1 2026

May 6, 2026, 7:00 AM EDT - 4 months ago

TG Therapeutics Reports First Quarter 2026 Financial Results and Raises BRIUMVI Revenue Guidance

Apr 30, 2026, 8:00 AM EDT - 4 months ago

TG Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 7:30 AM EDT - 4 months ago

TG Therapeutics to Host Conference Call on First Quarter 2026 Financial Results and Business Update

Apr 15, 2026, 7:30 AM EDT - 4 months ago

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

Mar 19, 2026, 7:30 AM EDT - 5 months ago

TG Therapeutics Secures an Additional $500 Million in Non-Dilutive Capital from Blue Owl and Expands Share Repurchase Program to $300 Million

Mar 9, 2026, 7:30 AM EDT - 6 months ago

Data Published in Neurology and Therapy Demonstrate Significant Reductions in Relapse and MRI Activity with BRIUMVI® in People with Highly Active Relapsing Multiple Sclerosis

Mar 6, 2026, 7:30 AM EST - 6 months ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2026 Annual Meeting

Mar 2, 2026, 7:01 AM EST - 6 months ago

Precision BioSciences Receives $7.5M in Proceeds from TG Therapeutics for Azer-cel Clinical Milestone in Multiple Sclerosis

DTIL

Feb 26, 2026, 8:30 AM EST - 6 months ago

TG Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

TG Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:30 AM EST - 6 months ago

TG Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:00 AM EST - 6 months ago

TG Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Feb 23, 2026, 7:30 AM EST - 6 months ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update

Feb 8, 2026, 4:17 PM EST - 7 months ago

TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis

Feb 6, 2026, 7:30 AM EST - 7 months ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Jan 15, 2026, 10:31 AM EST - 7 months ago

These under-the-radar stocks combine fast growth with big upside potential

AGYS ASTH BBT CORT CTRE DCOM DOCN

Jan 13, 2026, 4:30 PM EST - 7 months ago

TG Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 13, 2026, 4:30 PM EST - 7 months ago

TG Therapeutics Slides: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 7:30 AM EST - 8 months ago

TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

Dec 2, 2025, 12:30 PM EST - 9 months ago

TG Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 28, 2025, 7:30 AM EST - 9 months ago

TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 10 months ago

TG Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 3, 2025, 8:30 AM EST - 10 months ago

TG Therapeutics Earnings Call Transcript: Q3 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

TG Therapeutics Quarterly report: Q3 2025

Nov 3, 2025, 8:30 AM EST - 10 months ago

TG Therapeutics Earnings release: Q3 2025

Oct 31, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update

Oct 28, 2025, 7:30 AM EDT - 10 months ago

TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI

Sep 24, 2025, 9:10 AM EDT - 11 months ago

New Data for BRIUMVI® Demonstrate 89.9% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 6 Years of Continuous BRIUMVI Treatment

Sep 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

Sep 8, 2025, 10:30 AM EDT - 1 year ago

TG Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 7:30 AM EDT - 1 year ago

TG Announces Phase 3 Trial for Subcutaneous BRIUMVI Commenced Enrollment

Sep 4, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 10:20 AM EDT - 1 year ago

TG Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Sep 3, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Aug 4, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Quarterly report: Q2 2025

Aug 4, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings release: Q2 2025

Aug 4, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports Second Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance

Jul 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on Second Quarter 2025 Financial Results and Business Update

Jun 10, 2025, 10:40 AM EDT - 1 year ago

TG Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 9, 2025, 4:51 PM EDT - 1 year ago

Evercore ISI's Julian Emanuel says now is the time to buy small-caps

CNS LEU RMBS SFM

Jun 6, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 4, 2025, 12:50 PM EDT - 1 year ago

TG Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

May 27, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings Call Transcript: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Quarterly report: Q1 2025

May 5, 2025, 8:30 AM EDT - 1 year ago

TG Therapeutics Earnings release: Q1 2025

May 5, 2025, 7:00 AM EDT - 1 year ago

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics to Host Conference Call on First Quarter 2025 Financial Results and Business Update

Apr 18, 2025, 8:00 AM EDT - 1 year ago

TG Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Apr 7, 2025, 7:30 AM EDT - 1 year ago

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

Mar 7, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

Mar 4, 2025, 7:03 AM EST - 1 year ago

Privia Health, Corcept and three other low-key but high-earnings growth potential stocks to invest in 2025

CORT GILD PRVA TKO

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings Call Transcript: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Annual report: Q4 2024

Mar 3, 2025, 8:30 AM EST - 1 year ago

TG Therapeutics Earnings release: Q4 2024

Feb 27, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum

Feb 26, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2024 Financial Results and Business Update

Feb 18, 2025, 10:20 AM EST - 1 year ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK CYTK EXE KRYS MARA

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 13, 2025, 7:30 PM EST - 1 year ago

TG Therapeutics Slides: FY 2025

Jan 9, 2025, 7:30 AM EST - 1 year ago

TG Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 4, 2024, 7:36 AM EST - 1 year ago

20 stocks likely to lag the S&P 500 over the next year — for this one reason

CELH CENX CNXC CRSR CXM FLG GEO

Dec 3, 2024, 10:00 AM EST - 1 year ago

TG Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Healthcare Conference

Nov 29, 2024, 8:00 AM EST - 1 year ago

TG Therapeutics to Participate in the Evercore HealthCONx Conference

Cedenmo Sep. 10 at 3:59 PM

$TGTX I’m glad Agrawal asked about peak sales. Felt like he was trying to either jump start the stock price and/or trigger buyer interest?

1 · Reply

OlDocAngus Sep. 10 at 3:21 PM

$TGTX Neither do I.

0 · Reply

OlDocAngus Sep. 10 at 3:18 PM

1 · Reply

StockDreamin Sep. 10 at 2:49 PM

$TGTX cmon cmon

0 · Reply

ngyojiw Sep. 10 at 1:59 PM

$TGTX this drops faster than the overbought s&P lol

0 · Reply

Chartist0_0 Sep. 10 at 1:54 PM

$TGTX $XBI The bloom is off the XBI rose. Time to take cover.

1 · Reply

FUDrucker100 Sep. 10 at 1:47 PM

$TGTX wen $60? Wen moon?

4 · Reply

RookieRider Sep. 10 at 1:14 PM

$TGTX on vacation this week in Maine guys and gals. I see we are fading a bit. Need TG to rise so can get another monster Lobster 🦞

1 · Reply

NetworkNewsWire Sep. 10 at 1:12 PM

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market $QNTM $NVS $MRK $TGTX $BMY https://ibn.fm/A7zHr

1 · Reply

stu Sep. 10 at 12:40 PM

$TGTX https://ir.tgtherapeutics.com/news-releases/news-release-details/tg-therapeutics-participate-hc-wainwright-28th-annual-global

0 · Reply

Rickerthestockpicker1 Sep. 10 at 11:32 AM

$TGTX

0 · Reply

OlDocAngus Sep. 10 at 11:30 AM

$TGTX

0 · Reply

ngyojiw Sep. 10 at 11:29 AM

$TGTX looks like another red day. with CPI coming tomorrow too huhu. its never good when MW opens his mouth .

1 · Reply

Luckybreak Sep. 10 at 10:47 AM

$TGTX Long term retail investors in TGTX Our problem is that we are here for long term Little bit of Wall Street greed syndrome rubbed onto us The biggest investor /single investor in TGTX Says that we are at $ 1 billion in revenue for IV Briumvi He does also mentions that we are not close to multiple of earring that IVis capable of generating at peak So 2 Billion he clearly says is too little The same biggest single investor says Subq Briumvi expected to bring in double of that revenue In other words $4 billion peak revenue /conservative Then again patent extends to 2042 I ask long term investors /what else are you looking for Yes all we need now is patience Patience Patience When you build they shall come /BO will happen

0 · Reply

fodness Sep. 10 at 9:40 AM

$TGTX Seems odd that considerable time was spent on MG and schizophrenia at the Cantor fireside, but practically no mention of azer-cel knowing a readout is likely weeks to months away. Even stranger after the recent autoimmune CAR-T safety issues, that was an obvious question, and Cantor never went there.

2 · Reply

StockDreamin Sep. 10 at 8:47 AM

$TGTX cmon cmon

0 · Reply

jonyoyo Sep. 10 at 8:24 AM

$TGTX

0 · Reply

ngyojiw Sep. 10 at 4:07 AM

$TGTX tough days coming with PPI and CPI newskoo lol

0 · Reply

DonutHole2 Sep. 10 at 1:15 AM

$TGTX typically we bomb a lot more than xbi … interesting that while today was ‘not great,’ TG moved in sympathy w/xbi but did not overshoot as much as it frequently does

0 · Reply

Cedenmo Sep. 9 at 11:22 PM

$TGTX we’re sitting on a goldmine. If $2B IV + $2B SubQ peak sales too low, then total peak sales must be at least $5B just for B RMS franchise. Hell, Roche is practically handing us IV market on a silver platter. O biosimilars are gonna have a hard time competing with B thanks to our pricing already 25% cheaper than O.

2 · Reply

OlDocAngus Sep. 9 at 10:06 PM

$TGTX https://www.zerohedge.com/political/you-better-get-ready-war-socialists-call-war-streets-end-capitalism

1 · Reply

uhk_it_im_in Sep. 9 at 9:44 PM

$TGTX unfavorable Subq results are the only thing that could torpedo this. I believe we have a winner but never underestimate the power of Big Pharma and corruption within our government.

2 · Reply

Market Cap	8.53B
Revenue (ttm)	616.29M
Net Income (ttm)	447.18M
EPS (ttm)	N/A
PE Ratio	20.07
Forward PE	61.08
Profit Margin	72.56%
Debt to Equity Ratio	1.23

Volume	448,982
Avg Vol	2,104,826
Day's Range	N/A - N/A
Shares Out	153.07M
Stochastic %K	40%
Beta	1.67
Analysts	Sell
Price Target	$63.75